Alcon Q1 2023 Earnings Presentation

Q1 2023 Select financial highlights Core operating margin' 1Q23 1Q22 3rd party sales $2,333M $2,175M Sales of $2.3B, up 7%, or 11% cc¹ Surgical driven by consumables and equipment, partially offset by PCIOLS in South Korea Alcon Vision Care reflects strength in contact lenses and eye drops, including acquired products Favorable pricing in consumables, contact lenses and ocular health ~400 basis points (bps) negative impact from FX 1Q23 1Q22 20.6% 20.6% Operating margin of 11.5%, up 20 bps vs. 1Q22; up 170 bps cc¹ Core operating margin (COM) of 20.6%, in-line with 1Q22; up 130 bps cc¹ COM cc growth reflects improved underlying operating leverage from higher sales and manufacturing efficiencies, partially offset by unfavorable PCIOL mix in South Korea and higher R&D Negative -130 bps impact from FX on COM 1Q23 1Q22 Core diluted EPS¹ $0.68 $0.70 1Q23 diluted EPS of $0.35 up 3%, or 26% cc¹ 1Q23 core diluted EPS of $0.70, up 3%, or 14% cc¹ 1Q23 1Q22 Free cash flow¹ ($52M) ($19M) 1Q23 cash from operating activities (CfOA) of $85M; reflects increased collections from higher sales, tially offset by FX, higher transformation payments, other operating expenditures, including increased R&D, and higher tax payments due to timing 1. Constant currency, core operating margin, core diluted EPS and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found in the Appendix. 1Q23 free cash flow (FCF) reflects higher CfOA, lower capex FCF an outflow in both periods due to timing of annual bonus payment 6

View entire presentation